ROSOPATAMAB TETRAXETAN LUTETIUM LU-177
UNII JB9647672Z

Substance Identification & Data

This profile provides standardized clinical and technical data for Rosopatamab Tetraxetan Lutetium Lu-177, uniquely identified by the FDA Unique Ingredient Identifier (UNII) JB9647672Z.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2866236-96-4 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
JB9647672Z
CAS Registry Number
2866236-96-4
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
ROSOPATAMAB TETRAXETAN LUTETIUM LU-177
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
C38701
National Cancer Institute reference terminology for clinical and research data.
INN ID
12996
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Rosopatamab tetraxetan lutetium Lu-177
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Rosopatamab Tetraxetan Lutetium Lu-177. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

lutetium (<sup>177</sup>Lu) rosopatamab tetraxetan

Common Names & Synonyms

<sup>177</sup> LU-DOTA-ROSOPATAMAB
DOTA-HUJ-591 LU-177
H-gamma1 heavy chain (1-445) [VH Musmus/Homsap (Mus musculus IGHV1-26*01 (78.4%) -(IGHD) -IGHJ2*01 (92.9%) T123>L (110)/Homo sapiens IGHV1-69-2*01 (76.3%) -(IGHD) -IGHJ4*01 (92.9%) V124>L (111), CDR-IMGT [8.8.8] (26-33.51-58.97-104)) (1-115) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (212) (116-213), hinge 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfide with L-kappa light chain (1'-214') [V-KAPPA Musmus/Homsap (Mus musculus IGKV6-23*01 (81.8%) -IGKJ2*03 (72.7%) S120>P (100), L124>V (104), E125>D (105)/Homo sapiens IGKV1-13*02 (78.7%) -IGKJ3*01 (91.7%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153'), V101 (191') (108'-214')]; dimer (224-224'':227-227'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa; conjugated via the side chain nitrogen of an average of 4 lysine residues to lutetium (<sup>177</sup>Lu) radiolabelled 2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclodecan-1-yl]acetyl (tetraxetan, DOTA)
HUJ591-GS (177LU-J591)
Immunoglobulin G1, anti-(human prostate-specific membrane antigen) (human-Mus musculus monoclonal Huj591 γ1-chain), disulfide with human-Mus musculus monoclonal Huj591 κ-chain, dimer, N<sup>6</sup>-[2-[4,7,10-tris[(carboxy-κO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN<sup>1</sup>,κN<sup>4</sup>,κN<sup>7</sup>,κN<sup>10</sup>]acetyl-κO]-L-lysine complex with lutetium-<sup>177</sup>Lu
LUTETIUM (177LU) J591
Lutetium (177Lu) J591 [WHO-DD]
Rosopatamab tetraxetan lutetium Lu-177
TLX-591
TLX591
immunoglobulin G1-kappa, anti-[Homo sapiens FOLH1(folate hydrolase, prostate specific membrane antigen, PSMA)], lutetium (<sup>177<sup>Lu) radiolabelled tetraxetan conjugate
lutetium (<sup>177</sup>Lu) rosopatamab tetraxetan [INN]

External Clinical & Regulatory Resources

CAS
Common Chemistry
NCATS
Inxight Drugs
NLM
DailyMed Products
NCATS
GSRS Full Record
NIH
NCI Thesaurus